• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.巨细胞动脉炎缓解和复发的定义:文献检索数据与基于德尔菲共识的专家意见比较。
Ann Rheum Dis. 2011 Mar;70(3):447-53. doi: 10.1136/ard.2010.133850. Epub 2010 Nov 19.
2
Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.红细胞沉降率和C反应蛋白在评估风湿性多肌痛疾病活动度和严重程度中的应用:一项前瞻性随访研究
Semin Arthritis Rheum. 2000 Aug;30(1):17-24. doi: 10.1053/sarh.2000.8366.
3
Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.风湿性多肌痛的诊断、鉴别诊断及治疗
Drugs Aging. 2006;23(5):391-402. doi: 10.2165/00002512-200623050-00003.
4
Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.巨细胞动脉炎与风湿性多肌痛:系统评价。
JAMA. 2016 Jun 14;315(22):2442-58. doi: 10.1001/jama.2016.5444.
5
Definitions of and instruments for disease activity, remission and relapse in polymyalgia rheumatica: a systematic literature review.风湿性多肌痛中疾病活动、缓解和复发的定义及评估工具:一项系统文献综述
Rheumatology (Oxford). 2025 Feb 1;64(2):455-469. doi: 10.1093/rheumatology/keae428.
6
The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission.日常使用的风湿性多肌痛活动评分:缓解定义的建议
Arthritis Rheum. 2007 Jun 15;57(5):810-5. doi: 10.1002/art.22771.
7
[Methods for assessment of disease activity of polymyalgia rheumatica].[风湿性多肌痛疾病活动度评估方法]
Z Rheumatol. 2023 Jun;82(5):368-379. doi: 10.1007/s00393-023-01358-x. Epub 2023 May 15.
8
EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).欧洲抗风湿病联盟(EULAR)风湿性多肌痛反应标准:欧洲风湿性多肌痛协作组(ESCISIT小组委员会)倡议的结果
Ann Rheum Dis. 2003 Dec;62(12):1189-94. doi: 10.1136/ard.2002.002618.
9
Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.血浆纤维蛋白原与患者报告的结局指标共同改善风湿性多肌痛的管理:一项前瞻性研究。
J Rheumatol. 2014 May;41(5):931-7. doi: 10.3899/jrheum.131055. Epub 2014 Apr 1.
10
Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.急性期反应物与风湿性多肌痛复发/再发风险:一项前瞻性随访研究
Arthritis Rheum. 2005 Feb 15;53(1):33-8. doi: 10.1002/art.20901.

引用本文的文献

1
Vitamin D Status and Response to Supplementation as Predictive Factors for Early Remission in Polymyalgia Rheumatica: A Retrospective Longitudinal Investigation.维生素D状态及补充反应作为风湿性多肌痛早期缓解的预测因素:一项回顾性纵向研究
Nutrients. 2025 Aug 31;17(17):2839. doi: 10.3390/nu17172839.
2
Evaluation of the Glucocorticoid-Sparing Effect of Adding Methotrexate in Polymyalgia Rheumatica: A Single-Center Retrospective Study.甲氨蝶呤用于多肌痛性风湿症的糖皮质激素节省效应评估:一项单中心回顾性研究
Cureus. 2025 Jul 31;17(7):e89107. doi: 10.7759/cureus.89107. eCollection 2025 Jul.
3
Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort.托珠单抗治疗风湿性多肌痛的真实世界有效性和安全性:一项来自庆应义塾大学风湿性多肌痛队列的回顾性研究
Rheumatol Int. 2025 Aug 26;45(9):207. doi: 10.1007/s00296-025-05941-0.
4
Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.治疗巨细胞动脉炎的传统与新兴策略:新疗法洞察
J Clin Med. 2024 Oct 29;13(21):6492. doi: 10.3390/jcm13216492.
5
Polymyalgia rheumatica: An update (Review).风湿性多肌痛:最新进展(综述)
Exp Ther Med. 2023 Oct 5;26(6):543. doi: 10.3892/etm.2023.12242. eCollection 2023 Dec.
6
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.生物疗法治疗重症哮喘的临床缓解:来自英国重症哮喘注册研究的分析。
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00819-2023. Print 2023 Dec.
7
[Methods for assessment of disease activity of polymyalgia rheumatica].[风湿性多肌痛疾病活动度评估方法]
Z Rheumatol. 2023 Jun;82(5):368-379. doi: 10.1007/s00393-023-01358-x. Epub 2023 May 15.
8
New-onset giant cell arteritis with lower ESR and CRP level carries a similar ischemic risk to other forms of the disease but has an excellent late prognosis: a case-control study.红细胞沉降率(ESR)和C反应蛋白(CRP)水平较低的新发巨细胞动脉炎与其他形式的疾病具有相似的缺血风险,但预后良好:一项病例对照研究
Rheumatol Int. 2023 Jul;43(7):1323-1331. doi: 10.1007/s00296-023-05299-1. Epub 2023 Apr 7.
9
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛的靶向治疗建议。
Ann Rheum Dis. 2024 Jan 2;83(1):48-57. doi: 10.1136/ard-2022-223429.
10
Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica.风湿性多肌痛患者24个月完全缓解和复发的预测因素。
Clin Exp Med. 2023 Nov;23(7):3391-3397. doi: 10.1007/s10238-022-00976-0. Epub 2022 Dec 24.

本文引用的文献

1
BSR and BHPR guidelines for the management of polymyalgia rheumatica.英国风湿病学会(BSR)和英国国家医疗服务体系改善局(BHPR)关于风湿性多肌痛管理的指南。
Rheumatology (Oxford). 2010 Jan;49(1):186-90. doi: 10.1093/rheumatology/kep303a. Epub 2009 Nov 12.
2
[Polymyalgia rheumatica].[风湿性多肌痛]
Internist (Berl). 2009 Jan;50(1):51-7; quiz 58-9. doi: 10.1007/s00108-008-2274-x.
3
Epidemiology of osteoarthritis.骨关节炎的流行病学
Rheum Dis Clin North Am. 2008 Aug;34(3):515-29. doi: 10.1016/j.rdc.2008.05.007.
4
Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.风湿性多肌痛中的血清白细胞介素-6受体:复发/再发风险的潜在标志物。
Arthritis Rheum. 2008 Aug 15;59(8):1147-54. doi: 10.1002/art.23924.
5
Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids.接受甲氨蝶呤和类固醇治疗的风湿性多肌痛患者的长期随访
Clin Exp Rheumatol. 2008 May-Jun;26(3):395-400.
6
Validity of the polymyalgia rheumatica activity score in primary care practice.初级保健实践中风湿性多肌痛活动评分的有效性
Ann Rheum Dis. 2009 Apr;68(4):541-5. doi: 10.1136/ard.2008.088526. Epub 2008 May 13.
7
Performance of the polymyalgia rheumatica activity score for diagnosing disease flares.用于诊断疾病复发的风湿性多肌痛活动评分的性能
Arthritis Rheum. 2008 Feb 15;59(2):263-9. doi: 10.1002/art.23338.
8
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.美国关节炎及其他风湿性疾病患病率的估计。第二部分。
Arthritis Rheum. 2008 Jan;58(1):26-35. doi: 10.1002/art.23176.
9
Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey.制定风湿性多肌痛的分类标准:专家小组观点与更广泛调查的比较
J Rheumatol. 2008 Feb;35(2):270-7. Epub 2007 Nov 15.
10
Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.用依那西普治疗难治性风湿性多肌痛:一项开放性初步研究。
Arthritis Rheum. 2007 Dec 15;57(8):1514-9. doi: 10.1002/art.23095.

巨细胞动脉炎缓解和复发的定义:文献检索数据与基于德尔菲共识的专家意见比较。

Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

机构信息

Correspondence to Professor Michael Schirmer, Department of Internal Medicine I, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

出版信息

Ann Rheum Dis. 2011 Mar;70(3):447-53. doi: 10.1136/ard.2010.133850. Epub 2010 Nov 19.

DOI:10.1136/ard.2010.133850
PMID:21097803
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3033531/
Abstract

OBJECTIVE

To compare current definitions of remission and relapse in polymyalgia rheumatica (PMR) with items resulting from a Delphi-based expert consensus.

METHODS

Relevant studies including definitions of PMR remission and relapse were identified by literature search in PubMed. The questionnaire used for the Delphi survey included clinical (n=33), laboratory (n=54) and imaging (n=7) parameters retrieved from a literature search. Each item was assessed for importance and availability/practicability, and limits were considered for metric parameters. Consensus was defined by an agreement rate of ≥80%.

RESULTS

Out of 6031 articles screened, definitions of PMR remission and relapse were available in 18 and 34 studies, respectively. Parameters used to define remission and/or relapse included history and clinical assessment of pain and synovitis, constitutional symptoms, morning stiffness (MS), physician's global assessment, headache, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood count, fibrinogen and/or corticosteroid therapy. In the Delphi exercise a consensus was obtained on the following parameters deemed essential for definitions of remission and relapse: patient's pain assessment, MS, ESR, CRP, shoulder and hip pain on clinical examination, limitation of upper limb elevation, and assessment of corticosteroid dose required to control symptoms.

CONCLUSIONS

Assessment of patient's pain, MS, ESR, CRP, shoulder pain/limitation on clinical examination and corticosteroid dose are considered to be important in current available definitions of PMR remission and relapse and the present expert consensus. The high relevance of clinical assessment of hips was unique to this study and may improve specificity and sensitivity of definitions for remission and relapse in PMR.

摘要

目的

将现有的巨细胞动脉炎(PMR)缓解和复发的定义与基于德尔菲共识的专家意见中的项目进行比较。

方法

通过在 PubMed 中进行文献检索,确定了包含 PMR 缓解和复发定义的相关研究。用于德尔菲调查的问卷包括从文献检索中提取的临床(n=33)、实验室(n=54)和影像学(n=7)参数。每个项目都根据重要性和可用性/可行性进行评估,并为度量参数设定了限制。共识的定义是同意率≥80%。

结果

在筛选出的 6031 篇文章中,有 18 篇和 34 篇分别提供了 PMR 缓解和复发的定义。用于定义缓解和/或复发的参数包括疼痛和滑膜炎的病史和临床评估、全身症状、晨僵(MS)、医生总体评估、头痛、红细胞沉降率(ESR)、C 反应蛋白(CRP)、血细胞计数、纤维蛋白原和/或皮质类固醇治疗。在德尔菲调查中,就以下被认为是缓解和复发定义的基本参数达成了共识:患者的疼痛评估、MS、ESR、CRP、肩部和髋部疼痛的临床检查、上肢抬高受限,以及评估控制症状所需的皮质类固醇剂量。

结论

评估患者的疼痛、MS、ESR、CRP、肩部疼痛/临床检查受限和皮质类固醇剂量被认为是当前 PMR 缓解和复发定义以及本专家共识中的重要因素。对髋关节的临床评估的高度相关性是本研究独有的,这可能提高缓解和复发定义的特异性和敏感性。